Homepage > Company > Media > Pharma News > 2018 > Impax launches authorized Solodyn generic

Impax launches authorized Solodyn generic

Impax Labs has launched its authorized Solodyn generic (minocycline HCl, extended-release tablets). The drug is indicated to treat only inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients ages 12 years and older.

Impax’s authorized Solodyn generic will be available in 65- and 115-mg dosage strength. The product had U.S. sales of roughly $148 million for the 12 months ended December 2017, according to IQVIA data.

February 21, 2018

https://www.drugstorenews.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...